ADC Therapeutics SA - 8-K Filing
ADC Therapeutics announced topline results from its Phase 3 LOTIS-5 trial evaluating ZYNLONTA® in combination with rituximab for relapsed or refractory diffuse large B-cell lymphoma. The study met the primary endpoint of progression-free survival (PFS) with statistical significance (HR = 0.73; p-value = 0.008), showing a median PFS of 6.1 months vs. 4.7 months for R-GemOx, and demonstrated no detrimental effect on overall survival. The company plans to meet with the FDA in August ahead of an sBLA submission by Q4 2026. (Items: 7.01 Regulation FD Disclosure, 8.01 below, ADC Therapeutics SA (the “Company”) issued a press release and made available a presentation, copies of which are attached as Exhibit, 9.01 Financial Statements and Exhibits)
Tickers: $ADCT